NiKang Therapeutics® to Present Preliminary Results of Phase 1/2 Clinical Trial of NKT2152 in Patients with Previously Treated Advanced Clear Cell Renal Cell Carcinoma at ESMO 2024 Congress newsBy Elizabeth AspinallSeptember 9, 2024See the press release on Business Wire